Pharmaceuticals

In the chaotic, high-stakes world of pharma tradeshows, success is no longer about free pens. It's about strategy, psychology, and navigating regulations.

Nordicus Partners reveals promising data for gum disease and oral lesions, betting its future on a unique Nordic acquisition strategy and a Nasdaq uplisting.

A new clinical trial, backed by the Michael J. Fox Foundation, tests a radical idea: an oral drug derived from carbon monoxide to fight Parkinson's.

A new strategic partnership aims to overcome drug resistance in GI cancers by combining Lonza's advanced ADC platform with Antharis's targeted antibody expertise.

New Phase 3 data for Takeda's oveporexton shows it treats the root cause of narcolepsy, not just symptoms. A key FDA decision looms this year.

Tri Delta’s 27-year, $185M partnership with St. Jude is more than charity. It's a masterclass in grassroots economic power fueling life-saving innovation.

As AI promises to revolutionize medicine, enterprises face complex challenges. A new ISG study aims to chart the critical partner ecosystem.

As AI drug discovery faces a crucial test, Terray Therapeutics hires a proven dealmaker. Can Lisa Decker translate digital promise into clinical reality?

Big Pharma is pouring over $1 billion into AI to design complex drugs, trading lab guesswork for algorithms. It's a high-stakes play to fix a broken R&D model.

New clinical trial results for XWRAP® show a significant leap in healing diabetic ulcers, positioning Applied Biologics as a formidable player in a challenging field.

The journey from brand launch to retail shelf has shrunk from years to just 18 months. A new playbook reveals how TikTok data and GLP-1 drugs are the forces behind this massive shift.

With air quality plummeting, a new wellness market is booming. We investigate the science and business behind lung health supplements for wildfire season.

Sumitomo Pharma's new data reveals a potent combination therapy for myelofibrosis and decodes resistance in leukemia, shaking up a competitive oncology landscape.

The financial giant extends its massive Security and Resiliency Initiative north, targeting defense, energy, and supply chains to bolster regional stability.

A new precision drug, ART5803, is offering hope for a devastating brain disorder. Arialys Therapeutics is fast-tracking its development with key clinical trials.

A 23% national drop in overdose deaths signals progress, but regional disparities and a volatile drug supply show the fight is far from over.

Facing a 'going concern' warning and collapsing revenue, Splash Beverage Group is ditching drinks for drugs. Its investment in Avicanna is a desperate, yet strategic, pivot.

A new study offers hope for MS by promoting nerve repair, but the real story is the validation of a versatile stem cell platform for a new era of medicine.

New data reveals elevated cortisol in over 75% of hard-to-treat diabetes patients, paving the way for a novel drug to tackle treatment resistance.

While CEO Craig Chambliss's EY award makes headlines, the real story is Neurelis's disruption of epilepsy care and its ambitious pipeline for brain disorders.